Open an account

Rxsight

RXST · NASDAQ

$4.88+$0.19 (+4.05%)TodayMarket closed ·
Prev close $4.69

About RXST

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 461 full-time employees. The company went IPO on 2021-07-30. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is composed of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and related accessories. The LAL is an intraocular lens (IOL) made from the silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. Its LAL uses a silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. The LDD uses software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction.

Employees
461
Headquarters
Aliso Viejo, California
Listed
Jul 30, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
rxsight.com

RXST key statistics

Market cap
202.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
760.59K
Volume
453.94K
Open price
$4.71
High today
$4.92
Low today
$4.65
52 Week high
$13.22
52 Week low
$4.40

Rxsight (RXST) at a glance

Rxsight (RXST) last traded at $4.88, with a market cap of 202.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.65 and $4.92. The current price is 4.9% above the day's low and 0.8% below its high.

Volume so far is 453.94K shares, below the average of 760.59K shares a day.

Over the past year Rxsight has ranged from $4.40 to $13.22, and now sits 5% of the way up that range.

Rxsight met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.29 per share against an estimate of -$0.3365.

The average analyst price target is $7.95, 62.9% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

11%of 9 analyst ratings say Buy
  • Buy11.1%
  • Hold66.7%
  • Sell22.2%
Price target · 10 analystsAvg $7.95
Low
$5.55
Now
$4.88
High
$11.55

RXST earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 23.9% on average.

  1. Q3 FY24: reported -$0.16 per share against an estimate of -$0.2512
  2. Q4 FY24: reported -$0.15 per share against an estimate of -$0.1686
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.2203
  4. Q2 FY25: reported -$0.29 per share against an estimate of -$0.2485
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.3863
  6. Q4 FY25: reported -$0.22 per share against an estimate of -$0.339
  7. Q1 FY26: reported -$0.38 per share against an estimate of -$0.2871
  8. Q2 FY26: reported -$0.29 per share against an estimate of -$0.3365

RXST news

  • Press releaseBusiness Wire

    Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

  • Press releaseBusiness Wire

    Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

  • Press releaseBusiness Wire

    The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

  • Rishabh Mishra

    Stock Market Today: Dow Jones Futures Gain, S&P 500, Nasdaq 100 Slips As SpaceX Debuts On The Exchange—Rivian, Micron In Focus (UPDATED)

  • Press releaseBusiness Wire

    Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

  • Press releasePRNewswire

    Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • What 5 Analyst Ratings Have To Say About RxSight

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

Similar companies

Companies in the same industry as Rxsight

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.